COMBINATION THERAPY POTENT FOR TREATING BREAST CANCER

A study co-authored by a Loyola researcher and published in the New England Journal of Medicine is offering new hope to women with advanced breast cancer.

The study found that combining two drugs that normally are each given as single agents significantly extended the lives of women with metastatic breast cancer.

Kathy Albain,MD, a breast cancer specialist at Loyola University Medical Center, is among the main authors of the study.

The study found that women who initially took the drugs anastrozole and fulvestrant at the same time together lived more than six months longer than women who took anastrozole alone, with fulvestrant given later when the disease progressed.

“This study is the first to show that combination hormonal therapy alone without chemotherapy improves survival in advanced breast cancer,” Albain said.
“This most likely will change the standard of care for how we treat these patients.”

Anastrozole (brand name, Arimidex®) is a pill that is taken daily. It is in a class of medications called aromatase inhibitors.

It works by decreasing the amount of estrogen the body makes.

Fulvestrant (brand name Faslodex®) is given by injection. It binds to estrogen receptors, thereby blocking the effect estrogen has on cancer cells.

The study included 707 postmenopausal women who had metastatic breast cancer that was hormone-receptor-positive.

About half the women were randomly assigned to receive the standard regimen: treat first with anastrozole, and after the disease progresses, switch to fulvestrant.

The other half were randomly assigned to receive anastrozole and fulvestrantin combination.

Women who received the standard regimen survived a median of 41.3 months. Women who received the two drugs in combination survived a median of 47.7 months.

Among women who received the standard regimen, it took a median of 13.5 months for the disease to progress.

Among those who received the drugs in combination, it took 15 months before the disease progressed.

The combination treatment produced even greater benefits among women who had not previously taken tamoxifen.

Side effects generally were similar in both treatment groups, although only the combination group experienced the most severe side effects (one stroke and two pulmonary embolisms).

FAROUK AND ITS COMPONENTS

Many of you might have seen this:

It has been on the internet for some weeks now

I have kept it in my archive for long too ~

I just feel like sharing it now :_: as my own little way of making you cool off for the weekend

{{pli:z save the page or simply bookmark us to read subsequent and/or previous posts}}

enjoy >>>>>>>

¤ FAROUK: To collect bribe and deny it boldly

¤ FAROUKED: Past tense of farouk

¤ FAROUKER: A person who farouks

¤ FAROUKEE: A person who is farouked

¤ FAROUKISH: Having the appearance of or relating to bribery and denial

¤ FAROUKOLOGY: The study of bribe collection and denial of evidence

¤ FAROUKISM: The political ideology/concept of bribery and cover-ups

¤ FAROUKIOSIS: A chronic disorder of bribe taking and denial

¤ FAROUKMENT: A system of farouking

¤ FAROUKISTICALLY: Carried out or done in a way that suggests a farouk

¤ FAROUKICIDE: An act exhibited by a farouker that is capable of causing someone to farouk

¤FAROUKXY: Being in the mood or setting out strategies to farouk

¤ FAROUKTANCY: Identification and analysis of a farouked person(s) for decision making

¤ FAROUKIOLYSIS: The act of destroying or conceiving bribery evidence so as to frustrate prosecution

¤ FAROUKOMA: A sudden growth of greed that leads to an aborisation and an endless desire to demand and collect bribe without a pre-thought to realize the consequences thereof

¤ FAROUKECTOMY: A surgical procedure for the removal of faroukoma

share your comment(s)

SCIENTISTS DEVELOP DRUG FOR THE TREATMENT OF EBOLA VIRUS

Scientists at the National Microbiology Laboratory in Winnipeg have made a discovery in the treatment of the deadly Ebola virus.

They have developed a drug treatment that has been found to be 100 per cent effective in tests on animals when used within 24 hours of contact with the disease.

Dr. Gary Kobinger heads a team of about a dozen scientists at the laboratory who have been working intensively on a treatment for the Ebola virus for the past five years.

Their expectation is that the approach they used with Ebola can also be used to treat other deadly viruses.

The Winnipeg group isolated antibodies to the virus in mice and developed an easy-to-manufacture treatment.

While extremely effective if used 24-hours after contact, it has also been shown to be effective up to 48 hours after infection.

Ebola is transmitted by direct contact with the blood, secretions, organs or other body fluids of infected persons.

The deadly strains are found in parts of Central Africa.

Health care workers have also frequently been infected while treating Ebola patients.

The goal, once the drug receives regulatory approval, is to stockpile the drug for both patients and health workers in areas where it has emerged.

There currently is no vaccination to prevent infection of the Ebola virus.

The Zaire strain of Ebola is one of the most aggressive in the world. Up to 90 per cent of those infected die within days of exposure.

The World Health Organization says there have been more than 1,850 documented cases of the virus, which was first identified in Sudan and Zaire (now the Democratic Republic of the Congo) in 1976.

More than 1,200 have died of it.
Federal Health Minister Leona Aglukkaq congratulated the Winnipeg-based researchers on their achievement.

“This groundbreaking discovery is a remarkable achievement and exemplifies the world-class research conducted here in Canada,” she said in a press release.

Dr. Frank Plummer, chief science officer at the Public Health Agency of Canada, said Canadian researchers have seen first hand the terrible effects of the Ebola virus in Africa. “This discovery should pave the way for the development of a new drug that has the potential to save many lives,” he said in a statement.

While Ebola does not naturally occur in Canada, there is always a small risk that it could be imported into the country by an infected traveller.

Having a safe and effective treatment option at the ready is important to protect Canadians from that risk, scientists say.

The National Microbiology Laboratory is Canada’s leading public health infectious disease laboratory and the only facility in Canada that is permitted to study and work with live haemorrhagic fever viruses such as Ebola and other similarly highly infectious and deadly organisms.

PAPILO CLOCKS 36 TODAY read and watch video clip to wish him happy birthday

Born in Owerri, Imo State on August 1, 1976, former Eagles’ skipper [Nwankwo Kanu] clocks 36 today.

He is the most decorated Nigerian footballer in history, with over ten(10) awards to boast of, including a UEFA champions league medal, a UEFA cup medal and two African player of the year awards.

Kanu retired from International football after featuring in a testimonial match between Super Eagles and the rest of the world XI on June 12, 2011.
Click

to see picture

Below is another link to a clip showing some of Kanu’s beautiful displays

http://www.bing.com/videos/search?q=Nwankwo Kanu&FORM=VQFRVS

Happy Birthday Papilo